ロード中...
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted agents for the treatment of solid tumors. Concurrent PARP inhibition in Breast Cancer Susceptibility Gene (BRCA)-mutated or homologous recombination-deficient tumor cells can induce “synthetic lethality”, which targets two DNA re...
保存先:
| 出版年: | Cancer Manag Res |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove
2019
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6519338/ https://ncbi.nlm.nih.gov/pubmed/31191001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S200524 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|